中性粒细胞未恢复对侵袭性曲霉病患者结局的影响:SECURE试验事后分析
第42天全因死亡率在未恢复中性粒细胞的患者中(艾沙康唑45.0%,伏立康唑45.2%)远高于已恢复者(5.0% vs 5.9%)。两药疗效安全性相当,中性粒细胞恢复与结局改善相关。
要点
- 中性粒细胞未恢复者第42天全因死亡率约45%,恢复者约5%,差异显著。
- 艾沙康唑与伏立康唑在中性粒细胞减少的侵袭性曲霉病患者中疗效安全性相当。
- 中性粒细胞恢复与更好的临床结局相关,提示需关注中性粒细胞恢复状态。
核心结论
- 艾沙康唑与伏立康唑在中性粒细胞减少的侵袭性曲霉病患者中疗效和安全性相当。
- 中性粒细胞恢复与改善的结局相关,未恢复者死亡率显著更高。
研究设计与样本
- 患者接受艾沙康唑(n=78)或伏立康唑(n=64)治疗,主要终点为第42天全因死亡率。
主要发现
- 第42天全因死亡率:中性粒细胞未恢复者艾沙康唑45.0%、伏立康唑45.2%;已恢复者艾沙康唑5.0%、伏立康唑5.9%。
- 第7天全因死亡率:未恢复者艾沙康唑31.0%、伏立康唑29.8%;已恢复者艾沙康唑5.0%、伏立康唑5.9%。
- 治疗结束时全因死亡率:未恢复者艾沙康唑48.6%、伏立康唑36.4%;已恢复者艾沙康唑5.0%、伏立康唑14.3%。
- 艾沙康唑组未恢复者较恢复者全因死亡率显著更高(第7天P=0.031;第42天P<0.001;治疗结束P<0.001)。
- 伏立康唑组未恢复者较恢复者第42天全因死亡率显著更高(P=0.002),第7天和治疗结束时数值更高但无统计学显著性(P>0.05)。
临床怎么用
- 对中性粒细胞减少的侵袭性曲霉病患者,艾沙康唑和伏立康唑均可作为治疗选择。
- 临床应密切监测中性粒细胞恢复情况,未恢复者预后较差,需加强管理。
局限性
- 为事后分析,可能存在混杂因素,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, baseline neutropenia and lack of neutrophil recovery have been associated with poor outcomes in invasive aspergillosis (IA). It is unclear how treatment with the new Aspergillus-active triazoles isavuconazole and voriconazole affects outcomes in neutropenic patients with IA. METHODS: A post hoc analysis of the Phase 3 SECURE trial assessed patients with neutropenia (neutrophil count <0.5 × 109/L for >10 days at baseline) with IA (proven/probable) who had received either isavuconazole or voriconazole. The primary endpoint was all-cause mortality (ACM) through day 42. ACM in patients with resolved versus unresolved neutropenia at day 7 and overall success at end of treatment (EOT) were also assessed. RESULTS: One hundred and forty-two patients with neutropenia and IA were included (isavuconazole n = 78, voriconazole n = 64). ACM through day 42 (primary endpoint), day 7 and EOT were higher for patients with unresolved versus resolved neutropenia at each timepoint (day 42, unresolved: 45.0% isavuconazole, 45.2% voriconazole; resolved: 5.0% isavuconazole, 5.9% voriconazole; day 7, unresolved: 31.0% isavuconazole, 29.8% voriconazole; resolved: 5.0% isavuconazole, 5.9% voriconazole; EOT, unresolved: 48.6% isavuconazole, 36.4% voriconazole; resolved: 5.0% isavuconazole, 14.3% voriconazole). ACM was significantly higher for isavuconazole-treated patients with unresolved versus resolved neutropenia (day 7, P = 0.031; day 42, P < 0.001; EOT, P < 0.001). In voriconazole-treated patients, ACM was significantly higher among patients with unresolved versus resolved neutropenia at day 42 (P = 0.002) and numerically higher at day 7 and EOT (P > 0.05 for both). CONCLUSIONS: Isavuconazole had comparable efficacy and safety to voriconazole in neutropenic patients with IA. Resolution of neutropenia was associated with improved outcomes.
引用
- Kontoyiannis DP, Selleslag D, Mullane K, et al. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018. PMID: 29194488. doi:10.1093/jac/dkx423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。